Physician profile
Matthen Mathew
NPI 1467741306
$1,794.12
in general payments reported to CMS, 2019-2025
22 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.00 · 2021: $195 · 2022: $193 · 2023: $350 · 2024: $475 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $320.24 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Astrazeneca Pharmaceuticals LP | $308.22 | 2022-2025 | Tagrisso, Enhertu |
| Galvanize Therapeutics, INC | $250.72 | 2023-2025 | Aliya System |
| Daiichi Sankyo INC. | $125.65 | 2024-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $125.28 | 2021-2025 | |
| Array Biopharma INC | $113.65 | 2023-2025 | Mektovi, Lorbrena, Braftovi |
| Caris Mpi, INC. | $76.72 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $63.53 | 2021-2025 | |
| Salvin Dental Specialties, INC. | $60.00 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $53.33 | 2022-2023 | Epkinly |
| Incyte Corporation | $50.91 | 2021-2024 | Jakafi |
| Genzyme Corporation | $43.64 | 2021-2024 | |
| Astellas Pharma US INC | $42.30 | 2023-2024 | Padcev, Xospata |
| Jazz Pharmaceuticals INC. | $34.83 | 2021 | |
| Janssen Research & Development, LLC | $26.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.32 | 2021 | |
| Celgene Corporation | $20.32 | 2022 | |
| Gilead Sciences, INC. | $20.17 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $19.51 | 2023 | Sancuso |
| Amgen INC. | $14.78 | 2023 | Kyprolis |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthen Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.